In 2017, oncologist Talal Hilal, MD, treated a patient who had hepatocellular cancer by a new drug which didn't work, as mentioned in an updated guideline for cancer care (nivolumab, an immune checkpoint inhibitor). The patient died soon after, and later a large study failed to show that nivolumab improved outcomes for patients with hepatocellular cancer in the front-line setting.
Experts cite multiple obstacles for not providing care contrary to Current Clinical Guidelines - lack of, or conflicting evidence, lack of awareness about evidence; all that can conspire against the main goal of helping providers deliver consistent high-value care.
According to Dr Hilal, "There is no absolute certainty. Today's best practice may be abandoned tomorrow. Guidelines that propagate treatments without acknowledging their uncertainty can be harmful."
So, How often do you treat patients based on your experiences but contrary to Current Practice Guidelines?
Cast your vote now to share your opinion.